Viking Therapeutics (VKTX) Return on Capital Employed (2015 - 2026)

Viking Therapeutics has disclosed Return on Capital Employed across 12 years of filings, most recently posting 90.34% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 90.34%, down 7049.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 90.34% (down 7049.0% YoY), and the FY2025 annual result was 53.49%, down 2879.0% from the prior year.
• Return on Capital Employed came in at 90.34% for Q1 2026 at Viking Therapeutics, down from 60.43% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 13.38% in Q2 2024 to a low of 90.34% in Q1 2026.
• The 5-year median for Return on Capital Employed is 30.12% (2022), against an average of 34.29%.
• Across the five-year window, Return on Capital Employed soared 3381 bps in 2024 and sank 7049 bps in 2026, its largest moves.
• Viking Therapeutics' Return on Capital Employed stood at 48.3% in 2022, then soared by 41 bps to 28.29% in 2023, then surged by 40 bps to 16.85% in 2024, then slumped by 259 bps to 60.43% in 2025, then slumped by 49 bps to 90.34% in 2026.
• The last three Return on Capital Employed figures came in at 90.34% (Q1 2026), 60.43% (Q4 2025), and 36.28% (Q3 2025), per Business Quant data.